#### **Amendments to the Claims**

This Listing of the Claims will replace all prior versions, and listings, of claims in the application.

### **Listing of the Claims:**

1. (Previously Presented) A compound of formula I

wherein

each of R<sup>0</sup>, R<sup>1</sup>, and R<sup>2</sup>, independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkinyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>5</sub>-C<sub>10</sub>arylC<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxyC<sub>1</sub>-C<sub>8</sub>alkyl, aminoC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C<sub>1</sub>-C<sub>8</sub>alkoxy, hydroxyC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted or substituted C<sub>5</sub>-C<sub>10</sub>arylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylthio, C<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, halogen, carboxy, C<sub>1</sub>-C<sub>8</sub>alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted sulfamoyl, cyano or nitro;

- R<sup>3</sup> is C<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;
- Or the pair of adjacent substituents R<sup>2</sup> and R<sup>3</sup> forms –CH<sub>2</sub>-NH-CO- or -CH<sub>2</sub>-NH-SO<sub>2</sub>- or such pairs wherein NH is substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl;
- R<sup>4</sup> is hydrogen or C<sub>1</sub>-C<sub>8</sub>alkyl;
- each of R<sup>5</sup> and R<sup>6</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, halogen, carboxy, C<sub>1</sub>-C<sub>8</sub>alkoxycarbonyl, unsubstitued or substituted carbamoyl, cyano, or nitro; and
- each of  $R^7$ ,  $R^8$ ,  $R^9$ , and  $R^{10}$  independently is  $C_1$ - $C_8$ alkyl,  $C_2$ - $C_8$ alkenyl,  $C_2$ - $C_8$ alkinyl,  $C_3$ - $C_8$ cycloalkyl,  $C_3$ - $C_8$ cycloalkyl,  $C_5$ - $C_{10}$ aryl $C_1$ - $C_8$ alkyl, hydroxy $C_1$ - $C_8$ alkyl,  $C_1$ -

C<sub>8</sub>alkoxyC<sub>1</sub>-C<sub>8</sub>alkyl, aminoC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1, 2 or 3 hetero atoms selected from N, O and S, hydroxy, C<sub>1</sub>-C<sub>8</sub>alkoxy, hydroxyC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>arylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted or substituted or substituted heterocyclyloxy, or unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylthio, C<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, halogen, carboxy, C<sub>1</sub>-C<sub>8</sub>alkoxycarbonyl, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano or nitro; wherein R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> independently of each other can also be hydrogen;

or R<sup>7</sup> and R<sup>8</sup>, R<sup>8</sup> and R<sup>9</sup>, and/or R<sup>9</sup> and R<sup>10</sup> form together with the carbon atoms to which they are attached, a 5 or 6 membered carbocyclic or heterocyclic ring comprising 0, 1, 2 or 3 heteroatoms selected from N, O and S that is unsubstituted or substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy, halo-C<sub>1</sub>-C<sub>8</sub>-alkyl, hydroxyl, amino, substituted amino, halogen, carboxy, C<sub>1</sub>-C<sub>8</sub>alkoxycarbonyl, carbamoyl, cyano, or oxo;

A is C; and salts thereof.

- 2. (Currently Amended) A compound of formula I according to claim 1, wherein each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;
- R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted sulfamoyl;
- R<sup>3</sup> is C<sub>1</sub>-C<sub>8</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>-alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;
- R<sup>3</sup>-is C<sub>1</sub>-C<sub>8</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub>-alkylsulfonyl, C<sub>5</sub>-C<sub>10</sub>arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;

- or the pair of adjacent substituents R<sup>2</sup> and R<sup>3</sup> forms –CH<sub>2</sub>-NH-CO- or CH<sub>2</sub>-NH-SO<sub>2</sub>- or such pairs wherein NH is substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl;
- R⁴ is hydrogen or C₁-C<sub>8</sub>alkyl;
- R⁵ is hydrogen; C₁-C₂alkyl, halogen, haloC₁-C₂alkyl, cyano or nitro;
- R<sup>6</sup> is hydrogen;
- each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl;
- R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, C<sub>1</sub>-C<sub>8</sub>alkylsulfonyl, halogen, unsubstituted or substituted carbamoyl, unsubstituted or substituted sulfamoyl, cyano, or nitro; and
- R<sup>10</sup> is C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxyC<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, carboxy, carbamoyl, or unsubstituted or substituted sulfamoyl; or
- each pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup>, or R<sup>8</sup> and R<sup>9</sup> or R<sup>9</sup> and R<sup>10</sup>, is –NH-CH=CH-, -CH=CH-NH-, –NH-N=CH-, –CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-, -CH<sub>2</sub>
- 3. (Previously Presented) A compound of formula I according to claim 1, wherein each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted amino, or halogen;
- R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen;

- R<sup>3</sup> is C₁-C₂alkylsulfinyl, C₁-C₂-alkylsulfonyl, C₅-C₁₀arylsulfonyl, unsubstituted or substituted carbamoyl or unsubstituted or substituted sulfamoyl;
- or the pair of adjacent substituents R<sup>2</sup> and R<sup>3</sup> forms –CH<sub>2</sub>-NH-CO- or CH<sub>2</sub>-NH-SO<sub>2</sub>- or such pairs wherein NH is substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl;

R4 is hydrogen;

R<sup>5</sup> is hydrogen, halogen, haloC₁-C₀alkyl, or nitro;

R<sup>6</sup> is hydrogen;

- each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;
- R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and
- R<sup>10</sup> is C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, or halogen; or
- each pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup>, or R<sup>8</sup> and R<sup>9</sup> or R<sup>9</sup> and R<sup>10</sup>, is –NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-O-, or -O-CF<sub>2</sub>-O-;

A is C.

- 4. (Currently Amended) A compound of formula I according to claim 1, wherein each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4piperidyloxy;
- R<sup>1</sup> is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;

R<sup>3</sup> is sulfamoyl, methylsulfamoyl or propylsulfamoyl; er

the pair of adjacent substituents R<sup>0</sup>-and R<sup>1</sup>, or R<sup>1</sup>-and R<sup>2</sup>-is-O-CH<sub>2</sub>-O-, or the pair of adjacent substituents R<sup>2</sup> and R<sup>3</sup> is -CH<sub>2</sub>-NH-CO- or -CH<sub>2</sub>-NH-SO<sub>2</sub>-;

R4 is hydrogen;

R<sup>5</sup> is hydrogen, chloro, bromo, trifluoromethyl or nitro;

R<sup>6</sup> is hydrogen;

- each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, unsubstituted or substituted C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;
- R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub>alkyl, haloC<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>5</sub>-C<sub>10</sub>aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C<sub>1</sub>-C<sub>8</sub>alkoxy, haloC<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>5</sub>-C<sub>10</sub>aryloxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC<sub>1</sub>-C<sub>8</sub>alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted sulfamoyl, or nitro; and
- R<sup>10</sup> is C₁-C₀alkyl, haloC₁-C₀alkyl, C₁-C₀alkoxy, unsubstituted or substituted heterocyclylC₁-C₀alkoxy, unsubstituted or substituted amino, or halogen; or
- each pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup>, or R<sup>8</sup> and R<sup>9</sup> or R<sup>9</sup> and R<sup>10</sup>, is –NH-CH=CH-, -CH=CH-NH-, -NH-N=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-O-, or -O-CF<sub>2</sub>-O-;

A is C.

- 5. (Currently Amended) A compound of formula I according to claim 1, wherein each of R<sup>0</sup> or R<sup>2</sup> independently is hydrogen, piperazino, N-methylpiperazino or 1-methyl-4piperidyloxy;
- R<sup>1</sup> is hydrogen, piperazino, N-methylpiperazino, morpholino, 1-methyl-4-piperidinyloxy, 3-morpholinopropoxy or 2-morpholinoethoxy;
- R3 is sulfamoyl, methylsulfamoyl or propylsulfamoyl; er
- the pair of adjacent substituents R<sup>0</sup> and R<sup>1</sup>, or R<sup>1</sup> and R<sup>2</sup> is -O-CH<sub>2</sub>-O-, or the pair of adjacent substituents R<sup>2</sup> and R<sup>3</sup> is -CH<sub>2</sub>-NH-CO- or -CH<sub>2</sub>-NH-SO<sub>2</sub>-;
- R⁴ is hydrogen;
- R<sup>5</sup> is hydrogen, chloro, bromo, trifluoromethyl or nitro;
- R<sup>6</sup> is hydrogen;
- each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperidinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;
- R<sup>8</sup> is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-

- morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and
- R<sup>10</sup> is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or
- the pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup> or R<sup>8</sup> and R<sup>9</sup> is -O-CH<sub>2</sub>-O- or the pair of adjacent substituents R<sup>9</sup> and R<sup>10</sup> is -NH-CH=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>- CH<sub>2</sub>- or -O-CF<sub>2</sub>-O-;

A is C.

**6.** (Previously Presented) A compound of formula I according to claim 1, wherein each of R<sup>0</sup>, R<sup>1</sup> or R<sup>2</sup> is hydrogen:

R<sup>3</sup> is sulfamoyl, methylsulfamoyl or propylsulfamoyl;

R⁴ is hydrogen;

R<sup>5</sup> is chloro or bromo;

R<sup>6</sup> is hydrogen;

- each of R<sup>7</sup> and R<sup>9</sup> independently is hydrogen, methyl, isopropyl, trifluoromethyl, phenyl, o-, m- or p-methoxyphenyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, isopropoxy, phenoxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 2-(1-imidazolyl)ethoxy, dimethylamino, fluoro, morpholinocarbonyl, piperazinocarbonyl or cyclohexylcarbamoyl;
- R<sup>8</sup> is hydrogen, methyl, piperidino, piperazino, N-methylpiperazino, morpholino, methoxy, ethoxy, trifluoromethoxy, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy, 3-(N-methylpiperazino)-propoxy, methylamino, fluoro, chloro, sulfamoyl or nitro; and
- R<sup>10</sup> is methyl, butyl, methoxy, ethoxy, 2-(1-imidazolyl)ethoxy, methylamino, dimethylamino or fluoro; or
- the pair of adjacent substituents R<sup>7</sup> and R<sup>8</sup> or R<sup>8</sup> and R<sup>9</sup> is -O-CH<sub>2</sub>-O-, or the pair of adjacent substituents R<sup>9</sup> and R<sup>10</sup> is -NH-CH=CH-, -CH=N-NH-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-or -O-CF<sub>2</sub>-O-;

A is C.

**7.** (Previously Presented) The compound of formula I according to claim 1, wherein each of R<sup>0</sup>, R<sup>1</sup> or R<sup>2</sup> is hydrogen, R<sup>3</sup> is methylsulfamoyl, R<sup>4</sup> is hydrogen, R<sup>5</sup> is bromo, R<sup>6</sup> is hydrogen, each of R<sup>7</sup> and R<sup>8</sup> is methoxy, R<sup>9</sup> is hydrogen, and R<sup>10</sup> is methyl, and A is C.

- **8.** (Previously Presented) The compound of formula I according to claim 1, wherein each of R<sup>0</sup>, R<sup>1</sup> or R<sup>2</sup> is hydrogen, R<sup>3</sup> is methylsulfamoyl, R<sup>4</sup> is hydrogen, R<sup>5</sup> is bromo, R<sup>6</sup> is hydrogen, each of R<sup>7</sup> and R<sup>8</sup> is hydrogen, and the pair of adjacent substituents R<sup>9</sup> and R<sup>10</sup> is -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, and A is C.
- **9.** (Previously Presented) The compound 2-{5-Chloro-2-[4-(3-methylamino-pyrrolidin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide.
- 10. (Previously Presented) A process for the production of a compound of formula I according to claim 1, comprising reacting a compound of formula II

$$R^{1}$$
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{6}$ 
 $R^{6}$ 
 $R^{6}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{7}$ 

wherein  $R^0$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  are as defined in claim 1, and Y is a leaving group, with a compound of formula III

$$R^7$$
 $R^8$ 
 $R_{10}$ 
 $R^9$ 
 $R^{10}$ 
(III)

wherein A,  $R^7$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  are as defined in claim 1;


and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 1, into another compound of formula I as defined in claim 1;

and recovering the resulting compound of formula I in free from or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

**11.** (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.

- 12. (Cancelled).
- 13. (Previously Presented) A combination comprising a therapeutically effective amount of a compound according to claim 1 and one or more known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.
- 14. (Currently Amended) A method for the treatment of <u>breast tumors</u> neoplastic diseases and immune system disorders in a subject in need thereof which comprises administering an effective amount of a compound according to claim 1 or a pharmaceutical composition comprising same.
- **15.** (Currently Amended) A method for the treatment or prevention of a disease which responds to inhibition of focal adhesion kinase or/and IGF-1 Receptor comprising administering a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 16.-20. (Cancelled).
- **21.** (Previously Presented) The method according to claim 14, wherein the compound is 2-[5-Bromo-2-(2-methoxy-5-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide or a pharmaceutically acceptable salt thereof.
- 22. (Previously Presented) The method according to claim 14, wherein the compound is selected from 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, N²-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine and 2-{5-Chloro-2-[2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ylamino}-N-isopropyl-benzenesulfonamide, or a pharmaceutically acceptable salt thereof.
- **23.** (Previously Presented) A compound of the formula I shown in claim 1, selected from the group of compounds with the following names or formulae:
- 2-[2-(2,5-dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methylbenzenesulfonamide;
- 2-[5-bromo-2-(2,4-dimethoxy-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzenesulfonamide;

Com-	Rx
pound	
3-1	0 F
3-2	Me
3-3	MeO
3-4	F
3-5	OMe
3-6	OMe





3-15	OMe
3-16	Me Me
3-17	MeO Me
3-18	Me
3-19	OMe
3-20	Me
3-22	Me N

3-23	NH NH
3-24	o Me
3-25	MeO
3-26	Me
3-27	Me
3-28	Me
3-29	OEt

3-30	OEt
3-31	
3-32	
3-33	
3-34	Ac N
3-35	
3-36	F
3-37	CI F


3-38	F
3-39	
3-40	o o
3-41	S S
3-42	
3-43	H <sub>2</sub> N O







3-55	
3-56	
3-57	
3-58	
3-59	
3-60	OH
3-61	
3-62	

3-63	
3-64	_N
3-65	
3-66	°-
3-67	0-
3-68	NH <sub>2</sub>
3-69	







,

2-[5-bromo-2-(2,3-[difluoromethylenedioxy]phenylamino)-pyrimidin-4-ylamino]-benzenesulfonamide;


2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide;


a compound of the formula


Com-	Rx
pound	

No.	
7-1	
7-2	N N NH <sub>2</sub>
7-3	O N
7-4	
7-5	N O

7-6	
7-7	N Ac
7-8	
7-9	
7-10	
7-11	








7-28	N N
7-29	
7-30	

;

a compound of the formula


Com-	Rx
pound	
8-1	




;

## a compound of the formula

Com-	Rx
pound	
9-1	0
	N
	0






i

a compound of the formula


Com-	Rx
pound	
10-1	



;


a compound of the formula

0




Com-	Rx
pound.	


Com-	Ry
pound	
14-1	
14-2	
14-3	NH F



Compound	Rx
15-1	



Com-	Ry
pound	
16-1	
16-2	N N
16-3	0



a compound of the formula

a compound of the formula

Com-	Rx
pound.	

Com-	Rx
pound	
19-1	
19-2	
19-3	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~


19-4	N N N N N N N N N N N N N N N N N N N
19-5	N N N N N N N N N N N N N N N N N N N
19-6	O .
19-7	O N N
19-8	, o
19-9	o

19-10	
19-11	O F
19-12	
19-13	
19-14	o
19-15	o 

19-16	N N N
19-17	
19-18	N O
19-19	N N NH <sub>2</sub>
19-20	0
	\

19-21	0 F
19-22	O O O
19-23	NH OH
19-24	O N
19-25	F

19-26	F ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
19-27	
19-28	F O N
19-29	
19-30	



.

a compound of the formula

Com-	Rx
pound	
20-1	, , , , , , , , , , , , , , , , , , ,
20-2	O N Ac

20-3	0 F F
20-4	O F H
20-5	o o
20-6	
20-7	ZH ZH
20-8	

20-9	
20-10	N
20-11	O N
20-12	
20-13	

20-14	
20-15	O NH <sub>2</sub>
20-16	O N
20-17	O ZH
20-18	N N N N N N N N N N N N N N N N N N N
20-19	HO
20-20	O N N N N N N N N N N N N N N N N N N N

20-21	
20-22	o N
20-23	F
20-24	O F
20-25	o N
20-26	
20-27	

20-28	
20-29	
20-30	
20-31	
20-32	
20-33	
20-34	

i

a compound of the formula


Com-	Rx
pound	
21-1	
21-2	• • • • • • • • • • • • • • • • • • •
21-3	o

wherein Rx has one of the meanings given in the following table:

Com-	Rx
pound	
22-1	P 0
22-2	• • • • • • • • • • • • • • • • • • •
22-3	, o


a compound of the formula

Com-	Rx
pound	
23-1	
23-2	
23-3	THE STATE OF THE S
23-4	N N N N N N N N N N N N N N N N N N N
23-5	O N





Com-	Rx
	KX
pound	
24-1	O .
24-2	O N
24-3	o and a second s

Com-	Rx
pound	
25-1	



Com-	Rx
pound	
26-1	N
26-2	N Ac
26-3	N N N N N N N N N N N N N N N N N N N






26-13	N NH <sub>2</sub>
26-14	O NH <sub>2</sub>
26-15	Ac N
26-16	ZH Z
26-17	


26-18	N N N N N N N N N N N N N N N N N N N
26-19	
26-20	
26-21	N N N N N N N N N N N N N N N N N N N
26-22	NH O

26-23	
26-24	
26-25	NH NH
26-26	
26-27	OH


26-28	O H
26-29	
26-30	O F
26-31	
26-32	
26-33	




	T n
Com-	Rx
pound	
27-1	N O
27-2	N N N N N N N N N N N N N N N N N N N
27-3	N N
27-4	
27-5	0




Com-	Rx
pound	



28-6	200
28-7	O_N_O
28-8	
28-9	
28-10	






28-20	o Z
28-21	NH NH
28-22	
28-23	o z z o


28-24	
28-25	
28-26	T Z Z
28-27	N NH <sub>2</sub>

Com-	Rx
pound	



a compound of the formula

Com-	Rx
pound	



a compound of the formula

wherein Rx has one of the meanings given in the following table:

Com-	Rx
pound	
31-1	<b>1</b>
31-2	, o

.

a compound of the formula


wherein Rx has one of the meanings given in the following table:

Com-	Rx
pounds	
32-1	N Ac
32-2	0

ï

a compound of the formula


Com-	Rx
pound	



a compound of the formula

Com-	Ry
pound	
34-1	0
34-2	
34-3	0

34-4	o o
34-5	0
34-6	O O
34-7	CI N NH NH NH NH
34-8	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z



2-[5-bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N, N-dimethyl-benzenesulfonamide;

2-[5-bromo-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-5-fluoro-N-methyl-benzenesulfonamide;

7-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-2-methyl-2,3-dihydro-isoindol-1-one;

and a compound of the formula

Com-	Rx
pound	
12-2	

12-3	ОН
12-4	
12-5	
12-6	

or a pharmaceutically acceptable salt thereof.

## 24. (New) A compound of the formula

wherein Ry has the formula

or a pharmaceutically acceptable salt thereof.